Abstract Number: 3L • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Low Radiographic Progression and Sustained Efficacy through 4 Years in Patients with Active Ankylosing Spondylitis
Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, reported improved signs and symptoms of ankylosing spondylitis (AS) in the MEASURE 1 trial.1 Here, we report…Abstract Number: 238 • 2017 ACR/ARHP Annual Meeting
Power Dopper Ultrasonography Detects Superior Efficacy of Non-TNF Biologics Compared to Cycling of TNF Inhibitors in RA Patients Inadequate Response to First TNF Inhibitors
Background/Purpose: Efficacy of cycling of TNF inhibitors, judged by composite measures, is inferior to non-TNF biologics in patients with RA inadequate response to previous TNF…Abstract Number: 1537 • 2017 ACR/ARHP Annual Meeting
Determinants of Patient-Reported Improvement after Administration of Biological Treatment in Axial Spondyloarthritis: A Cross-Sectional Study
Background/Purpose: Efficacy of biological treatment in patients with axial spondyloarthritis (SpA) varies and is dependent on both disease-related and patient-related factors. The goal of this…Abstract Number: 280 • 2017 ACR/ARHP Annual Meeting
Reasons Why Patients Failed Vaccinations Vs Influenza and Pneumococcus. Monocentric Cross-Sectional Study.
Background/Purpose: immunosuppressive therapies and bDAMRDs expecially, increase the risk of infections. According to the EULAR guidelines, all patients affected by autoimmune/inflammatory diseases should receive vaccinations…Abstract Number: 1558 • 2017 ACR/ARHP Annual Meeting
Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis
Background/Purpose: Psoriasis is a complex disorder with cutaneous and rheumatological manifestations affecting 2-3% of the population of the Western world. The prevalence of hypertension (HTN)…Abstract Number: 421 • 2017 ACR/ARHP Annual Meeting
Serum Calprotectin Is Not Predictive for Successful Dose Reduction or Discontinuation of TNF Inhibitors in RA Patients with Low Disease Activity
Background/Purpose: Dose reduction and discontinuation of TNF inhibitors (TNFi) have been shown feasible in a large proportion of RA patients with low disease activity.1 To…Abstract Number: 1908 • 2017 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety Results of a Global Phase 3 Trial of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment
Background/Purpose: In patients (pts) with active rheumatoid arthritis (RA) despite DMARD treatment, sirukumab, a human monoclonal antibody that selectively binds to the IL-6 cytokine with…Abstract Number: 422 • 2017 ACR/ARHP Annual Meeting
No Added Predictive Value of Serum Calprotectin for Treatment Response to Adalimumab or Etanercept in RA Patients
Background/Purpose: To date, no clinically useful baseline biomarkers have been found to predict response to TNF inhibitor (TNFi) treatment .1 Calprotectin was shown to be…Abstract Number: 2284 • 2017 ACR/ARHP Annual Meeting
Use of Biological Therapies in Adult Patients Diagnosed with Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events with Biologic Therapies (BIOBADASER)
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. The advent of new biological drugs has changed the prognosis and…Abstract Number: 470 • 2017 ACR/ARHP Annual Meeting
Clinical Response to the First Biologic in Rheumatoid Arthritis Patients with Moderate Disease in a Real World Clinical Cohort
Background/Purpose: While most randomized trials assess the effectiveness of biologic DMARDs (bDMARDs) in rheumatoid arthritis (RA) patients with high disease activity, in the real world…Abstract Number: 2290 • 2017 ACR/ARHP Annual Meeting
Comparing Effectiveness of Early Initiation of Biologic Treatment for Newly Diagnosed Juvenile Idiopathic Arthritis Using a Novel Statistics Causal Inference Method Applied to Observational Data
Background/Purpose: We compare the effectiveness of two approaches to treat Juvenile idiopathic arthritis (JIA): early combination of biologic and non-biologic disease modifying anti rheumatic drugs…Abstract Number: 524 • 2017 ACR/ARHP Annual Meeting
Predictors of Mortality in RA Patients before Biologic Therapy
Background/Purpose: Several studies have evaluated mortality risk factors in rheumatoid arthritis (RA) but that are no data regarding baseline predictors of mortality in patients under…Abstract Number: 2416 • 2017 ACR/ARHP Annual Meeting
Histopathological Change Caused By Biological Treatment in Rheumatoid Arthritis Synovial Tissue
Background/Purpose: Multiple studies addressing the effects of biologics on the synovial tissue in rheumatoid arthritis (RA) patients have been reported. There are, however, few studies…Abstract Number: 605 • 2017 ACR/ARHP Annual Meeting
Ixekizumab Exhibits a Favorable Safety Profile during 24 Weeks of Treatment in Subjects with Active Psoriatic Arthritis: Integrated Safety Analysis of Two Randomized, Placebo Controlled, Phase III Clinical Trials
Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets IL-17A. The objective of this analysis is to report the integrated safety of…Abstract Number: 2437 • 2017 ACR/ARHP Annual Meeting
Long-Term Effect of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, on Radiographic Progression in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global Phase 3 Trial
Background/Purpose: In the SIRROUND-D study, sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, significantly reduced radiographic progression…
- 1
- 2
- 3
- …
- 10
- Next Page »